EBS
Emergent BioSolutions Inc.
EBS lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
EBS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Weak |
EBS's cash flow is currently strong, and its revenue is stable, but its profitability and balance sheet are weak.
EBS PE Valuation
EBS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 16x next year's earnings.
EBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect EBS to return to profit, with revenue growing.
EBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.38 | — |
| Q3 2026 | -$5.01 | -450% |
| Q2 2026 | -$3.46 | -234% |
| Q1 2026 | -$0.19 | +$2.39 |
| Q4 2025 | $0.93 | +$4.53 |
| Q3 2025 | $1.43 | +$5.48 |
| Q2 2025 | $2.58 | +$13.77 |
| Q1 2025 | -$2.58 | +$8.38 |
| Q4 2024 | -$3.60 | +$11.18 |
EBS has swung to a loss: it lost $5.01 per share over the past year, after a profit the year before.
EBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $110M | -52% |
| Q2 2026 | $234.3M | +66% |
| Q1 2026 | $156.1M | -30% |
| Q4 2025 | $148.7M | -24% |
| Q3 2025 | $231.1M | -21% |
| Q2 2025 | $140.9M | -45% |
| Q1 2025 | $222.2M | -26% |
| Q4 2024 | $194.7M | -30% |
EBS's revenue has slid since its 2021 peak: $110M last quarter, down 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -34% | -67 points |
| Q2 2026 | -53% | -55 points |
| Q1 2026 | 6.7% | -16 points |
| Q4 2025 | -19% | -14 points |
| Q3 2025 | 33% | +11 points |
| Q2 2025 | 1.1% | +81 points |
| Q1 2025 | 22% | +9.2 points |
| Q4 2024 | -4.9% | +11 points |
EBS's operating margin was −34% last quarter, down 67 points from the same quarter a year ago.
EBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.8M | +$102.5M |
| Q2 2026 | $54M | -48% |
| Q1 2026 | -$36.2M | -$21.4M |
| Q4 2025 | $73.8M | +$155.4M |
| Q3 2025 | -$5.7M | -104% |
| Q2 2025 | $103.5M | +141% |
| Q1 2025 | -$14.8M | +$58.6M |
| Q4 2024 | -$81.6M | -494% |
EBS still generates free cash flow, though less than at its 2021 peak: $188M over the past year.
EBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -300K shares |
| 1 year | -9.2% | -5.2M shares |
| 3 years | -1% | -500K shares |
| 5 years | -4.5% | -2.4M shares |
| Available history | -2.1% | -1.1M shares |
EBS has 51M diluted shares, down 9.2% from a year ago, with $27M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100,000 |
| Q2 2026 | $9M |
| Q1 2026 | $9M |
| Q4 2025 | $9.1M |
| Q3 2025 | $8.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
EBS spent $27M buying back its own shares over the past year.
EBS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 15.6x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 67.1x | High |
| Q4 2024 | 5,642.0x | High |
| Q3 2021 | 1.1x | Healthy |
EBS's net debt is about 16 years of its operating earnings (EBITDA), up from 1.9 years a year ago.
EBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 56.9 | Neutral |
EBS's weekly RSI is 42 (neutral) and its Stochastic is 57 (neutral).
EBS PE vs Healthcare Sector
| Metric | EBS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EBS has no meaningful PE right now: it lost money over the past year.
EBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.44 | 8.5% below |
| 20 week MA | $6.48 | 9.1% below |
| 50 week MA | $8.41 | 30% below |
| 100 week MA | $8.14 | 28% below |
| 200 week MA | $7.37 | 20% below |
EBS is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
EBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $93.8 | +74% |
| 2021 | $93.8 | $45.5 | -51% |
| 2022 | $45.5 | $11.0 | -76% |
| 2023 | $11.0 | $2.40 | -78% |
| 2024 | $2.40 | $8.27 | +245% |
| 2025 | $8.27 | $12.4 | +50% |
| 2026 YTD | $12.4 | $5.89 | -53% |
EBS's yearly returns have swung widely, from +245% in 2024 to −78% in 2023. It's down 53% so far in 2026.